medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Number 1

<< Back Next >>

Arch Neurocien 2023; 28 (1)

Role of manganese in the pathophysiology of hepatic encephalopathy: scoping review protocol

Pérez-Neri I, Sandoval H, Malvaso A, Indika Neluwa-Liyanage R, Alarcon-Ruiz CA, Ebrahimian M, Ríos C

Language: Spanish
References: 28
Page: 25-30
PDF size: 167.94 Kb.


ABSTRACT

Introduction: Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver disease and/ or portosystemic blood shunting, characterized by alterations in alertness, personality, cognition, and motor functions. Its severity can be classified into four grades from mild to coma. This disease may affect several brain regions, including the cingulate gyrus, insular cortex, and globus pallidus. The pathophysiology of HE is thought to be multifactorial, involving manganese accumulation in the brain, the damaging effect of ammonia on glial cells, etc. Previous studies describe the pathophysiology of HE or the effect of manganese on the central nervous system. However, there is no review addressing both topics from an integrative perspective through a systematic methodology. This scoping review aims to evaluate the role of manganese in HE. Methods: Published studies (all publication types) will be retrieved from Web of Science, Medline, Scopus, EBSCOhost, Ovid, and Google Scholar. Inclusion criteria: studies reporting manganese levels in any biological sample sample of patients with HE, any experimental model reporting the effect of manganese administration on neuroprotection in models of liver damage, or showing an effect on manganese levels in the liver and/or the brain. Exclusion criteria: studies reporting subjects exposed occupationally or environmentally to manganese, or written in languages different than Spanish or English that could not be appropriately translated, or whose full-text files could not be retrieved. Either clinical or preclinical studies will be analyzed separately but might be discussed together. Data summaries will be presented in graphs, figures, and tables. A narrative synthesis will be presented. This protocol complies with PRISMA-P.


REFERENCES

  1. Butterworth RF. Hepatic encephalopathy in alcoholic cirrhosis (Encefalopatíahepática en la cirrosis alcohólica). Manual de neurología clínica. 2014;125:589-602.doi: 10.1016/B978-0-444-62619-6.00034-3

  2. Feltracco P, Cagnin A, Carollo C, Barbieri S, Ori C. Neurologicaldisorders in liver transplant candidates: Fisiopatología y evaluaciónclínica. Transplantation Reviews. 2017; 31(3):193-206. doi: 10.1016/j.trre.2017.02.006

  3. AG. Hepatic Encephalopathy. Clínicas Veterinarias de Norteamérica:Práctica de Pequeños Animales. 2017; 47(3):585-99. doi: 10.1016/j.cvsm.2016.11.008

  4. Sureka B, Bansal K, Patidar Y, Rajesh S, Mukund A, Arora A.Neurologicmanifestations of chronic liver disease and liver cirrhosis.Curr Probl Diagn Radiol. 2015; 44(5):449-61. doi: 10.1067/j.cpradiol.2015.03.004

  5. Elwir S, Rahimi RS. Hepaticencephalopathy: An update on thepathophysiology and therapeutic options. Revista de hepatología clínica ytraslacional. 2017; XX:1-10. doi: 10.14218/JCTH.2016.00069

  6. Pérez-Neri I, Ríos-Castañeda C. La inhibición de la óxido nítrico sintasamediada por glutamina podría explicar la “paradoja de la arginina”. ArchNeurocien. 2021; 26(2):7-9. doi: 10.31157/archneurosciencesmex.v26i2.277

  7. Hardy G. Manganeso ennutrición parenteral: Quién, cuándo y por quédebemos suplementar. Gastroenterology. 2009; 137(5):S29-S35. doi:10.1053/j.gastro.2009.08.011

  8. Rivera-Mancía S, Ríos C, Montes S. Acumulación de manganeso en elSNC y patologías asociadas. BioMetales. 2011; 24(5):811-25. doi:10.1007/s10534-011-9454-1

  9. Pérez-Neri I, Diéguez-Campa CE, Sandoval H, Chávez VA, Castro-Martínez E, Ríos C. Therapeutic potential of dehydroepiandrosterone forParkinson’s disease: scoping review protocol. Arch Neurocien. 2022; enprensa.

  10. Rosca EC, Tudor R, Cornea A, Simu M. Parkinson’sdisease in Romania:A scoping review protocol. Brain Sci. 2021;11(2):251. doi: 10.3390/brainsci11020251

  11. Polhemus AM, Bergquist R, Bosch de Basea M, Brittain G, Buttery SC,Chynkiamis N, et al. Walking-related digital mobility outcomes as clinicaltrial endpoint measures:Protocol for a scoping review. BMJ Open.2020;10(7):e038704. doi: 10.1136/bmjopen-2020-038704

  12. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, etal. PRISMA 2020 explanation and elaboration: updated guidance andexemplars for reporting systematic reviews. BMJ. 2021; 372:n160. doi:10.1136/bmj.n160

  13. EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, etal. PRISMA forabstracts: reporting systematic reviews in journal andconference abstracts. PLoS Med. 2013;10(4):e1001419. doi: 10.1371/journal.pmed.1001419

  14. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.Preferred reporting items for systematic review and meta-analysis protocols(PRISMA-P) 2015:Elaboración y explicación. BMJ. 2015;350:g7647.doi: 10.1136/bmj.g7647

  15. AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMAExtension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.Ann Intern Med. 2018;169(7):467-73. doi: 10.7326/M18-0850

  16. E, Munn Z, editores. Manual de Síntesis de la Evidencia del JBI. JBI;2020.https://synthesismanual.jbi.global. doi: 10.46658/JBIMES-20-01

  17. Tanila T, Tenhunen H, Hirvonen P. Valuemechanisms in the implementationof intelligent patient flow management system - a multiple case study. StudHealth Technol Inform. 2020;270:708-12. doi: 10.3233/SHTI200252

  18. Strech D, Synofzik M, Marckmann G. Systematic reviews of empiricalbioethics. J Med Ethics. 2008;34(6):472-7. doi: 10.1136/jme.2007.021709

  19. ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al.PRISMA-S:An extension to the PRISMA Statement for Reporting LiteratureSearches in Systematic Reviews. Syst Rev. 2021;10(1):39. doi: 10.5195/jmla.2021.962

  20. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, LefebvreC. PRESS Peer Review of Electronic Search Strategies: 2015 GuidelineStatement. J Clin Epidemiol. 2016;75:40-6. doi: 10.1016/j.jclinepi.2016.01.021

  21. WM, de Jonge GB. Mejora de la eficiencia y la confianza en la búsquedasistemática de bibliografía.EAHIL+ ICAHIS+ ICLC. 2015.

  22. Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface,coronaviruses and COVID -19. Clin Exp Optom. 2020;103(4):418-24.doi: 10.1111/cxo.13088

  23. Pérez-Neri I, González-Aguilar A, Sandoval H, Pineda C, RíosCPotencial terapéuticode la neuromodulación por ultrasonidos en ladisminución del dolor neuropático: Evidencia clínica y experimental. CurrNeuropharmacol. 2021;19(3):334-48. doi: 10.2174/1570159X18666200720175253

  24. McKeown S, Mir ZM. Consideraciones para la realización de revisionessistemáticas:Evaluating the performance of different methods forde-duplicating references. Syst Rev. 2021;10(1):38. doi: 10.1186/s13643-021-01583-y

  25. Bozada T, Borden J, Workman J, Del Cid M, Malinowski J, Luechtefeld T.Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review.Front Artif Intell. 2021;4:685298. doi: 10.3389/frai.2021.685298.eCollection 2021

  26. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C,Kamel C, et al. Cochrane Rapid Reviews Methods Group offersevidence-informed guidance to conduct rapid reviews. J Clin Epidemiol.2021;130:13-22. doi: 10.1016/j.jclinepi.2020.10.007

  27. Haddaway NR, McGuinness LA. PRISMA 2020: R package and ShinyAppfor producing PRISMA 2020 compliant flow diagrams (Versión 0.0.2).medRxiv. 2021.doi: 10.5281/zenodo.5082518

  28. Usher R, Stapleton T. Approaches for assessing decision-making capacityin older adults:A scoping review protocol. Síntesis de Evidencia del JBI.2020;18(4):832-40. doi: 10.11124/JBISRIR-D-19-00068




2020     |     www.medigraphic.com